ClinicalTrials.gg
Sign In
CompletedNCT01475045ANASAUpdated Nov 21, 2011

ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)

An observational study in Asthma and Chronic Obstructive Pulmonary Disease, sponsored by Elpen Pharmaceutical Co. Inc.. Completed at 2 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-21.

Sponsored by Elpen Pharmaceutical Co. Inc. · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
1,160
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to compare patients' satisfaction from the use of three different inhalation devices by using the FSI-10 questionnaire

Read the detailed description

Patients are requested to reply to FSI-10 questionnaire regarding their satisfaction from inhalation devices. Patients are on 3 different asthma inhalation devices with combination treatment (Turbuhaler, Diskus, Elpenhaler)

02

Conditions studied

  • Asthma
  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
03

In context

Asthma

4,010 studies on the registry are indexed under Asthma; 514 are open to participants now.

This study's enrollment of 1,160 is above the median of 150 across 993 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Elpen Pharmaceutical Co. Inc. is the lead sponsor of 45 studies on the registry; 7 are open to participants now.

Browse Elpen Pharmaceutical Co. Inc. studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Three subgroups of patients who are already in their inhalation treatment (devices: Discus, Elpenhaler, Turbuhaler) are asked to complete the FSI-10 questionnaire valid in Greek language. The questionnaire responses indicate their satisfaction by their treatment devices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 18 years old, both genders who are on their inhalation treatment at least two months before study enrollment,
  • Who are able to be compliant to study procedures

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years old,
  • Patients who are on their inhalation treatment less than two months before study enrollment
  • Patients who are not able to be compliant to study procedures
05

Study design

Time perspective
Prospective
Enrollment
1,160 participants (actual)

Groups and cohorts

  • Turbuhaler inhaler use
  • Discus inhaler use
  • Elpenhaler inhaler use
06

What researchers measure

Primary outcomes

  1. Patients' satisfaction

    Patients' replies to FSI-10 questionnaire valid in Greek language

    Time frame: all study period (5 months)

Secondary outcomes

  1. Patients devices' use

    Time frame: all study period (5 months)

07

Study locations

2 sites
  • 7th Pulmonary Clinic, Sotiria Hospital
    Athens, Greece
  • Sotiria Hospital
    Athens, Greece
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Apr 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2011
First posted
Nov 21, 2011
Start
Jan 2011
Primary completionActual
Apr 2011
CompletionActual
Sep 2011
Last update
Nov 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01475045
Lead sponsor
Elpen Pharmaceutical Co. Inc.
Responsible party
Sponsor
First posted
Nov 21, 2011
Start date
Jan 2011
Primary completion
Apr 2011
Completion
Sep 2011
Last update
Nov 21, 2011

Study contacts

Asimina Gaga
principal investigator · 7th Pulmonary Clinic, Sotiria Hospital of Athens

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma →

Other studies from this sponsor

Elpen Pharmaceutical Co. Inc. →

Start the discussion